Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats

被引:31
作者
Zakharova, ES
Danysz, W
Bespalov, AY
机构
[1] Abbott Labs, CNS Pharmacol, D-67008 Ludwigshafen, Germany
[2] Merz Pharmaceut, Preclin R&D, D-60318 Frankfurt, Germany
[3] Pavlov Med Univ, Inst Pharmacol, Lab Behav Pharmacol, St Petersburg 197089, Russia
关键词
nicotine; drug discrimination; nicotinic receptor antagonist; NMDA receptor antagonist; metabotropic glutamate receptor antagonist; dopamine receptor antagonist; rat;
D O I
10.1007/s00213-004-2067-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Antagonists acting at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors inhibit various phenomena associated with exposures to nicotine (e.g., tolerance, sensitization, dependence, and intravenous self-administration). These effects are often discussed in terms of nicotine-induced glutamate release with subsequent glutamate-dependent stimulation of dopamine metabolism and neuronal plasticity in brain areas critically involved in drug-addiction mechanisms. However, it is also well established that certain types of NMDA receptor antagonists (channel blockers) potently bind to nicotinic receptors and may act as nicotinic receptor antagonists. Objectives: The present study aimed to evaluate the discriminative-stimulus effects of the NMDA receptor channel blockers (+)MK-801, dextromethorphan, and memantine in rats trained to discriminate nicotine from its vehicle. Methods: Adult male Wistar rats were trained to discriminate 0.6 mg/kg nicotine from saline under a two-lever, fixed-ratio 10 schedule of food reinforcement. During test sessions, injections of (+)MK-801 (0.03-0.3 mg/kg, i.p.), dextromethorphan (30 mg/kg, s.c.), or memantine (1-10 mg/kg, i.p.) were co-administered with s.c. nicotine (0.075-0.6 mg/kg; interaction tests) or saline (generalization tests). Additional interaction and generalization tests were conducted with the selective nicotinic receptor antagonists mecamylamine (0.1-3 mg/kg, s.c.) and MRZ 2/621 (0.3-10 mg/kg, i.p.), and the mGlu5 receptor antagonist MPEP (3-10 mg/kg, i.p.). In generalization tests, none of the compounds produced any appreciable levels of substitution for nicotine. The nicotine discriminative-stimulus control was dose dependently attenuated by mecamylamine (ED50=0.67 mg/kg) and MRZ 2/621 (ED50=9.7 mg/kg). Both agents produced a marked downward shift in the nicotine dose-response curve. Memantine and MPEP slightly attenuated nicotine discriminative-stimulus effects, while (+)MK-801 and dextromethorphan did not affect the nicotine-appropriate responding. NMDA receptor channel blockers, such as (+)MK-801, dextromethorphan, and memantine, have minimal interactions with the discriminative-stimulus effects of nicotine.
引用
收藏
页码:128 / 135
页数:8
相关论文
共 34 条
[1]   Interactions between N-methyl-D-aspartate receptor antagonists and the discriminative stimulus effects of morphine in rats [J].
Bespalov, AY ;
Beardsley, PM ;
Balster, RL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 60 (02) :507-517
[2]   Effect of MK-801 at the human alpha 7 nicotinic acetylcholine receptor [J].
Briggs, CA ;
McKenna, DG .
NEUROPHARMACOLOGY, 1996, 35 (04) :407-414
[3]   Nicotine cue: Lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine [J].
Brioni, JD ;
Kim, DJB ;
ONeill, AB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 301 (1-3) :1-5
[4]   Open-channel blockers at the human α4β2 neuronal nicotinic acetylcholine receptor [J].
Buisson, B ;
Bertrand, D .
MOLECULAR PHARMACOLOGY, 1998, 53 (03) :555-563
[5]  
ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346
[6]   Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies [J].
Danysz, W ;
Parsons, CG ;
Kornhuber, J ;
Schmidt, WJ ;
Quack, G .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) :455-468
[7]  
Fu YT, 2000, J PHARMACOL EXP THER, V294, P458
[8]   2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist [J].
Gasparini, F ;
Lingenhöhl, K ;
Stoehr, N ;
Flor, PJ ;
Heinrich, M ;
Vranesic, I ;
Biollaz, M ;
Allgeier, H ;
Heckendorn, R ;
Urwyler, S ;
Varney, MA ;
Johnson, EC ;
Hess, SD ;
Rao, SP ;
Sacaan, AI ;
Santori, EM ;
Veliçelebi, G ;
Kuhn, R .
NEUROPHARMACOLOGY, 1999, 38 (10) :1493-1503
[9]  
GILLING KE, 2002, ABSTR SOC NEUROSCI, V28
[10]   Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors [J].
Glick, SD ;
Maisonneuve, IM ;
Kitchen, BA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 448 (2-3) :185-191